Deutenzalutamide in mCRPC: Meaningful Benefit in the HC‑1119‑04 Trial

Nature reports the results of the HC‑1119‑04 trial, a randomized, multicenter, double‑blind, placebo‑controlled phase 3 study of deutenzalutamide (HC‑1119) in metastatic castration‑resistant prostate cancer (mCRPC) after treatment with abiraterone and docetaxel. The trial was conducted in China and enrolled 417 patients, with 276 randomized to deutenzalutamide 80 mg once daily and 141 to placebo. All patients had previously failed abiraterone; about 68% had also received docetaxel.

The main endpoint was radiographic progression‑free survival (rPFS), defined as time from randomization to radiographic progression or death. Deutenzalutamide significantly improved rPFS compared with placebo, with a hazard ratio of 0.58 (95% CI 0.439–0.770; p = 0.001), indicating a 42% reduction in the risk of progression or death. Numeric results show that the median rPFS was 5.55 months in the deutenzalutamide arm versus 3.71 months in the placebo arm, a difference of about 1.8 months at the median. In patients who had failed both abiraterone and docetaxel, the hazard ratio was even lower, around 0.49, suggesting a slightly larger effect in the more heavily treated subgroup.

Overall survival analyses were more mixed. The final prespecified OS analysis, based on 325 deaths across both arms, showed a hazard ratio of 0.95 (95% CI 0.76–1.20; p = 0.697), which means there was no statistically significant difference between the two groups. However, sensitivity analyses that adjusted for post‑trial treatments, including subsequent taxane‑based chemotherapy and other androgen‑receptor‑targeted agents, suggested a possible survival benefit with deutenzalutamide, with OS hazard ratios between 0.65 and 0.73 depending on the model. This implies that the drug may improve survival in real‑world practice, but the effect is partially masked by later therapies in the trial design.

Safety data were collected in all patients who received at least one dose of study treatment. About 22% of patients on deutenzalutamide experienced at least one serious adverse event, compared with 15% on placebo. The most common serious events were anemia, low platelets, and low lymphocytes, mostly graded as moderate rather than life‑threatening. Grade 3 or higher anemia was more frequent with deutenzalutamide than with placebo. Importantly, the Nature‑published report notes that there were no seizures or falls during the trial, which is relevant because other androgen‑receptor inhibitors in this class have been associated with these neurological toxicities.

In summary, deutenzalutamide provides a statistically robust improvement in rPFS in men with mCRPC who have progressed after abiraterone and docetaxel, with a hazard ratio of 0.58 and median rPFS of 5.55 versus 3.71 months. The gain at the median is modest in absolute terms, but it occurs in a setting with limited options, and sensitivity analyses hint at a possible survival advantage that is not yet fully confirmed. The safety profile is broadly similar to other agents in this family, with added hematologic toxicity but no signal of seizures or falls.

Source.